Clinical Trial Update: Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluated the safety and immune response of a multi-epitope peptide melanoma vaccine using GM-CSF DNA as an adjuvant in patients with AJCC …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Multi-epitope peptide melanoma vaccine with GM-CSF DNA adjuvant

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | EARLY_Phase 1 | Status: COMPLETED